Ultragenyx CEO talks the company's path to profitability in developing drugs for rare diseases
Dr. Emil Kakkis, Ultragenyx founder & CEO, joins 'Closing Bell Overtime' to talk drug trials and development, its path to profitability and more.
Видео Ultragenyx CEO talks the company's path to profitability in developing drugs for rare diseases канала CNBC Television
Видео Ultragenyx CEO talks the company's path to profitability in developing drugs for rare diseases канала CNBC Television
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
Opening Bell, November 4, 2022
Office loan modifications jump: Trepp report
Executive Edge: Dismal Memorial Day weekend for movies
Breaking down shares of Hilton, Expedia and Match Group
Options Action: What to expect from Dell next week
Office loan modifications jump: Here’s what you need to know
Lockheed Martin sees record order volume in 2022 as earnings beat estimates
Regions Wealth's McKnight explains the best time to invest in the market
Cramer’s Mad Dash: Norwegian Cruise Line
Market has plenty of momentum as long as 10-year stays below 5%, says MAI's Chris Grisanti
Freedman: Housing is suffering from artificial constraint on inventory
There's room for more than one beneficiary in the AI chips space, says KeyBanc's John Vinh
VanEck CEO on the timeline for a spot Ethereum ETF
Leasing is back: Here's what you need to know
Road to November election
Finding investment opportunities as AI heads to mobile devices
Detrick: Upward market bias is still intact
Jensen Huang rises on billionaires list after strong Nvidia earnings
T-Mobile to acquire most of U.S. Cellular in $4.4 billion deal
Nothing wrong with market leaders like Nvidia continuing to lead, says Trade Idea's Michael Nauss
Opening Bell: May 28, 2024